SCHEDULE: Squadron Funds Acquire 5.6% Stake in Quince Therapeutics

Squadron Master Fund LP, along with its investment advisor Squadron Capital Management LLC and key individuals, has reported beneficial ownership of 5.6% of Quince Therapeutics, Inc. common stock.

Summary

• Squadron Master Fund LP, managed by Squadron Capital Management LLC, has acquired a 5.6% stake in Quince Therapeutics, Inc.
• The total number of shares beneficially owned by Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank is 55,173.
• This ownership percentage is based on 977,963 shares of common stock outstanding as of June 29, 2026, following a reverse stock split.
• The filing is made under Schedule 13G, indicating passive investment intent.
• Squadron Capital Management LLC is identified as an investment adviser, and Messrs. Sesterhenn and Blank are partners with investment discretion.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake acquisition by an investment entity, with no immediate negative indicators.

Positives

• Acquisition of a significant stake (5.6%) by an investment entity suggests confidence in Quince Therapeutics' potential.
• The filing is made under Schedule 13G, which typically signifies a passive investment approach, not an attempt to control the company.
• The reporting entities are established investment management firms and individuals with investment expertise.

Negatives

• No specific negative financial or operational information is disclosed in this Schedule 13G filing.
• The filing does not provide details on the acquisition cost or the specific strategy behind the investment.

Risks

• The investment is subject to market fluctuations and the overall performance of Quince Therapeutics.
• Potential for future changes in beneficial ownership or investment strategy by Squadron Master Fund LP.

Future Outlook

This filing does not contain forward-looking statements or specific guidance from Quince Therapeutics. The outlook pertains to the investment position of Squadron Master Fund LP.

Management Comments

• Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that they are the beneficial owner of any of the securities reported herein.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by an investment fund like Squadron Master Fund LP in a biotechnology or therapeutics company like Quince Therapeutics is common. Such filings often precede or follow other corporate actions or reflect a strategic investment thesis based on the company's pipeline or market position.

Stakeholder Impact

• Shareholders: May view the entry of an institutional investor as a positive signal, potentially increasing interest in the stock. However, the passive nature of the filing suggests no immediate impact on control.
• Management of Quince Therapeutics: Will be aware of the significant stake held by Squadron Master Fund LP, which could influence future strategic decisions or investor relations efforts.
• Creditors: No direct impact indicated, as the filing concerns equity ownership and not debt.

Next Steps

• Monitor future filings from Squadron Master Fund LP and Quince Therapeutics for any changes in ownership or corporate strategy.
• Observe Quince Therapeutics' operational and financial performance to assess the investment's progress.

Key Dates

Keywords

Quince Therapeutics, Squadron Master Fund LP, Squadron Capital Management LLC, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Stake Acquisition